2024
Results of SurVeil Versus IN.PACT Admiral Paclitaxel Coated Balloons in Femoropopliteal Arteries: Outcomes of the Randomised TRANSCEND Study Through 24 Months
Brodmann M, Gray W, Schneider P, Kurzmann-Guetl K, Schweiger L, Zeller T, Thieme M, Kilaru S, Bachinsky W, Feldman R, Holden A, Varcoe R, Lansky A, Rosenfield K, Investigators T. Results of SurVeil Versus IN.PACT Admiral Paclitaxel Coated Balloons in Femoropopliteal Arteries: Outcomes of the Randomised TRANSCEND Study Through 24 Months. European Journal Of Vascular And Endovascular Surgery 2024 PMID: 39615582, DOI: 10.1016/j.ejvs.2024.11.351.Peer-Reviewed Original ResearchFemoropopliteal artery diseasePrimary safetyPrimary patencyTRANSCEND studiesNon-inferiorityArtery diseaseRutherford stage 2Procedure related deathNon-inferiority clinical studyTarget lesion revascularisationTarget vessel revascularisationPaclitaxel coated balloonTarget limb amputationPrimary efficacyEfficacy endpointBinary restenosisClinical studiesFemoropopliteal arteriesSecondary outcomesRelated deathsCoated balloonsPatientsMonthsEfficacyPatency
2023
The Supreme Biodegradable Polymer DES in Acute and Chronic Coronary Syndromes: A PIONEER III Substudy
Hussain Y, Saito S, Curtis M, Kereiakes D, Baumbach A, Zidar J, McLaurin B, Dib N, Smits P, Díaz V, Cequier Á, Hofma S, Pietras C, Dressler O, Issever M, Windecker S, Leon M, Lansky A, Investigators I. The Supreme Biodegradable Polymer DES in Acute and Chronic Coronary Syndromes: A PIONEER III Substudy. Journal Of The Society For Cardiovascular Angiography & Interventions 2023, 2: 100629. PMID: 39130696, PMCID: PMC11307614, DOI: 10.1016/j.jscai.2023.100629.Peer-Reviewed Original ResearchTarget lesion failureAcute coronary syndromeChronic coronary syndromePrimary end pointCoronary syndromeDP-EESClinical presentationMajor adverse cardiac eventsEnd pointAdverse cardiac eventsBiodegradable polymer DESPrevious revascularizationLesion failureCardiac eventsCurrent smokersIII trialsLess diabetesCCS groupStent thrombosisPatientsRelative safetyDurable polymerSyndromeMonthsInteraction P
2015
Will this trial change my practice? The Dual Antiplatelet Therapy (DAPT) study - 12 or 30 months of dual antiplatelet therapy after drug-eluting stents.
Grundeken MJ, Lansky A, Tanguay JF, Gershlick A, Baumbach A, Cuisset T. Will this trial change my practice? The Dual Antiplatelet Therapy (DAPT) study - 12 or 30 months of dual antiplatelet therapy after drug-eluting stents. EuroIntervention 2015, 11: 364-5. PMID: 26196757, DOI: 10.4244/eijv11i3a71.Peer-Reviewed Original Research
2012
Whole Blood Gene Expression Testing for Coronary Artery Disease in Nondiabetic Patients: Major Adverse Cardiovascular Events and Interventions in the PREDICT Trial
Rosenberg S, Elashoff MR, Lieu HD, Brown BO, Kraus WE, Schwartz RS, Voros S, Ellis SG, Waksman R, McPherson JA, Lansky AJ, Topol EJ, for the PREDICT Investigators. Whole Blood Gene Expression Testing for Coronary Artery Disease in Nondiabetic Patients: Major Adverse Cardiovascular Events and Interventions in the PREDICT Trial. Journal Of Cardiovascular Translational Research 2012, 5: 366-374. PMID: 22396313, PMCID: PMC3349850, DOI: 10.1007/s12265-012-9353-z.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAngioplasty, Balloon, CoronaryCoronary AngiographyCoronary Artery BypassCoronary Artery DiseaseFemaleGene Expression RegulationGenetic Predisposition to DiseaseGenetic TestingHumansIschemic Attack, TransientLogistic ModelsMaleMiddle AgedMyocardial InfarctionOdds RatioPhenotypePredictive Value of TestsPrognosisProspective StudiesReproducibility of ResultsRisk AssessmentRisk FactorsStrokeTime FactorsUnited StatesConceptsMajor adverse cardiovascular eventsCoronary artery diseaseObstructive coronary artery diseaseGene expression scoreAdverse cardiovascular eventsCardiovascular eventsArtery diseaseClinical risk scoreGroup of patientsNegative predictive valueGene expression testingNondiabetic patientsPREDICT trialAngiography patientsGES groupPREDICT studyRisk scorePatientsPredictive valueExpression scoreRevascularizationEvent ratesDiseaseMonthsExpression testingA PERIPHERAL BLOOD GENE EXPRESSION SCORE FOR CORONARY ARTERY DISEASE IN NON-DIABETIC PATIENTS IDENTIFIES PATIENTS AT LOW RISK FOR MAJOR CARDIOVASCULAR EVENTS AND INTERVENTIONAL PROCEDURES IN THE NEXT 12 MONTHS
Kraus W, Voros S, Schwartz R, Ellis S, Waksman R, Tahirkheli N, Lieu H, Elashoff M, Rosenberg S, McPherson J, Lansky A, Topol E. A PERIPHERAL BLOOD GENE EXPRESSION SCORE FOR CORONARY ARTERY DISEASE IN NON-DIABETIC PATIENTS IDENTIFIES PATIENTS AT LOW RISK FOR MAJOR CARDIOVASCULAR EVENTS AND INTERVENTIONAL PROCEDURES IN THE NEXT 12 MONTHS. Journal Of The American College Of Cardiology 2012, 59: e1383. DOI: 10.1016/s0735-1097(12)61384-9.Peer-Reviewed Original Research
2000
Late total occlusion after intracoronary brachytherapy for patients with in-stent restenosis
Waksman R, Bhargava B, Mintz G, Mehran R, Lansky A, Satler L, Pichard A, Kent K, Leon M. Late total occlusion after intracoronary brachytherapy for patients with in-stent restenosis. Journal Of The American College Of Cardiology 2000, 36: 65-68. PMID: 10898414, DOI: 10.1016/s0735-1097(00)00681-1.Peer-Reviewed Original ResearchConceptsLate total occlusionPlacebo patientsStent restenosisIntracoronary radiationIrradiated groupAntiplatelet therapyTotal occlusionAcute myocardial infarctionEntire study groupUnstable anginaIntracoronary brachytherapyMyocardial infarctionRadiation protocolStudy groupLate thrombosisPatientsRestenosisMultivariate analysisMaximum doseMean timeNew stentTime of radiationVessel wallMonthsOverall rate